What are CAR-T cells?

CAR T cells, or chimeric antigen receptor T cells, are a type of genetically engineered immune cell that targets cancer cells in a patient's body. They are modified T cells extracted from a patient's blood and reprogrammed with CAR molecules that allow them to recognize and attack cancer cells. Once infused back into the patient, the CAR-T cells multiply and actively seek out and destroy cancer cells.

What is a chimeric antigen receptor?

A chimeric antigen receptor (CAR) is a receptor protein artificially engineered to attach to the surface of immune cells . It consists of an extracellular domain that binds to specific antigens on cancer cells, and an intracellular domain that activates the immune cell to kill the targeted cancer cell. CARs are engineered in the laboratory and can be used in immunotherapy to treat cancer by enhancing the immune system's ability to destroy cancer cells.

How are CAR-T cells made?

CAR T cells are made by collecting T cells from a patient's blood and genetically engineering them to express a chimeric antigen receptor (CAR) that recognizes and binds to a specific antigen on the cancer cell's surface. The engineered CAR-T cells are expanded in the lab and then infused back into the patient. Once inside, the CAR-T cells locate and bind to cancer cells, triggering an immune response that destroys the cancer cells.

Solutions

Online Inquiry

One-Stop CAR-B Therapy Development Solution

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Services Platforms Advantages Resources Related Sections

Over the past decade, great progress has been made in the field of immunotherapy, especially in the field of T cell therapy. Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability in the elimination of a variety of tumors. While, as more studies focused on B cells, researchers have found that the engineered B cells also have great therapeutic potential in various diseases.

Based on advanced technology and years of research, Creative Biolabs has developed high-quality custom services covering the entire CAR-B therapy development process to best suit customer's technical, program, and budget requirements which can greatly assist customer's research, preclinical investigation, and clinical stage development.

CAR-B Therapy Development

Our one-stop CAR-B therapy development services include but not limited to:

One-Stop CAR-B Therapy Development

Biomarker Identification & Selection

De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
Selection of the most suitable CAR-B therapy targets with greater potency and lower toxicity

One-Stop CAR-B Therapy Development

CAR Design & Construction

Design and construction of CARs
Smart™ CAR platform for the next generation CAR discovery
Customized lentiviral or retroviral CAR construction

One-Stop CAR-B Therapy Development

CAR-B In Vitro Assay

CAR expression validation
CAR-B cell proliferation
Multiplex cytokine screening
Cytotoxicity test against target cells

One-Stop CAR-B Therapy Development

Hybridoma-Immunogenomic engineering Platform

A platform for the immunogenomic reprogramming of hybridoma cells, leading to the rapid generation of cell lines that both surface express and secrete full-length antibodies.

CAR-B Cell Platforms

Despite the classical 1st-4th generations of CARs, our Smart™ CAR platform allows to provide construction services of novel CAR designs, such as Dual CAR, TriCAR, Modular CAR, Logic-gated CAR.

Smart™ CAR Construction

We have established a safer approach to cell therapy through the transient expression and non-viral delivery of one or more mRNA molecules into PBMCs or isolated immune cells.

mRNA-Based CAR Cell Platform

Such methods include knocking out endogenous genes to construct allogeneic universal CAR-T cells, destroying inhibitory receptors and integration of the CAR cassette.

CRISPR-edited CAR Cell Technology

Key Advantages

Our CAR-B therapy development services harness the power of two main advantages:

Gene delivery:

As the best pseudotype candidate, using the LVs pseudotyped with the BaEV envelope to achieve efficient B-cell gene transfer, which can facilitate efficient transduction of resting and stimulated human B cells. This system will be useful in B cell lines, and the range of alternative glycoproteins can be screened for optimal infectivity.

Fig 1. Pseudotyping of lentiviral vectors.

Analysis of lentiviral vectors. (Gutierrez-Guerrero, et al., 2020) Fig 1. Pseudotyping of lentiviral vectors.¹

B cell genome engineering:

CRISPR/Cas9 system has been widely used in recent years due to its advantages of high specificity, high activity, and simple design. The CRISPR design algorithms will be used to develop effective knock-out strategies to remove endogenous BCR (B cell receptor) expression from a B cell line.

Creative Biolabs' scientists are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing CAR-B development services to reduce the overall project development timeline for our clients. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

Infographic Support Knowledge

Evolution of Chimeric Antigen Receptor Design

B Cells in Cancer Biology

Overview of Chimeric Antigen Receptors

Chimeric antigen receptor (CAR) can combine the extracellular antigen recognition domain from antibodies with the immune cell signaling domain to redirect T cell specificity and induce potent antitumor activity. CAR is an artificial transmembrane receptor that connects the extracellular antigen recognition domain, hinge domain (HD), transmembrane domain (TMD), and intracellular signal transduction domain in series.

B Cell-based Immunotherapy

B cells are lymphocytes essential for the humoral immune response, secreting antibodies to clear foreign antigens. They originate from hematopoietic stem cells in the bone marrow and differentiate into mature B cells through stages involving VDJ recombination for diverse B cell receptors. Mature B cells migrate to peripheral lymphoid organs, where they encounter antigens and receive help from T follicular helper cells (Tfh) to enter germinal centers. There, they undergo somatic hypermutation and class switch recombination, enhancing antibody affinity and function, and differentiate into plasma cells or memory B cells. B cells can also develop in the meninges, highlighting their role in neuroimmune regulation. B cell-mediated immune responses include T-cell-dependent and T-cell-independent mechanisms. B cell-based immunotherapies, such as monoclonal antibodies targeting B cells and adoptive transfer of modified B cells, offer promising cancer treatments by enhancing or modulating immune responses.

Related Sections

Reference

Gutierrez-Guerrero, Alejandra et al. "Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy." Viruses vol. 12,9 1016.